Related Experiment Video
Updated: Sep 15, 2025

Author Spotlight: Advancing Facial Rejuvenation Therapy with Post-Laser Salicylic Acid Application
Published on: September 27, 2024
Clinical Efficacy Comparisons Between Poly-L-Lactic Acid Injections and Non-Ablative 1565-nm Fractional Laser for
Huanhuan Qu1, Li Wang1, Wuyan Xin1
1Department of Dermatology, Xijing Hospital, The Fourth Military Medical University, Xi'an, Shaanxi, China.
Background:
Despite numerous treatment modalities for striae distensae (SD), a definitive gold standard therapy remains unidentified.
Aims:
This study aims to evaluate and compare the efficacy of injectable poly-L-lactic acid (PLLA) with a 1565-nm non-ablative fractional laser (NAFL) in treating SD located in the abdominal area.
Methods:
40 women with SD were randomly assigned to one of four treatment groups: (1) control, (2) PLLA, (3) 1565-nm NAFL, and (4) a combination of PLLA and 1565-nm NAFL. Participants, except those in the control group, underwent three treatment sessions at monthly intervals. Antera 3D imaging was used to collect data at baseline (T0) and 3 months post-treatment (T4). Collagen fibers were analyzed via immunohistochemical staining, while elastic fibers were assessed using picrosirius red and Masson staining at both T0 and T4.
Results:
The overall efficacy scores for the PLLA, 1565-nm NAFL, and PLLA + 1565-nm NAFL groups were 5.70 ± 1.25, 3.60 ± 2.12, and 6.70 ± 2.21, respectively. Post-treatment evaluations demonstrated substantial decreases in SD volume from T0 to T4, with reductions of -1.96 ± 1.53 in the PLLA group, -0.70 ± 0.67 in the 1565-nm NAFL group, and -1.48 ± 1.35 in the PLLA + 1565-nm NAFL group. The combined and PLLA groups exhibited significant reductions in area compared to the 1565-nm NAFL and control groups. Histological analysis confirmed the presence of PLLA particles in the treated area without inflammatory reactions 1 month post-final injection.
Conclusions:
PLLA injections are more effective than 1565-nm NAFL in SD treatment, enhancing collagen production without inducing inflammation in treated skin.
Trial Registration:
Clinicaltrials.gov: NCT05827913.

